Skip to main content
All Posts By

admin

BioTalk Crab Trap Preview gif

7th Annual BioHealth Capital Region Crab Trap Preview

By BioTalk with Rich Bendis Podcast, News

BioTalk Crab Trap Preview gif

Crab Trap Judges and Sponsors, Sally Allain, MSc., MBA Head, JLABS @ Washington, DC Johnson & Johnson Innovation โ€“ JLABS, Srujana Cherukuri, Ph.D., Chief Executive Officer, Noble Life Sciences, Inc. & Lora Green, Partner, Wilson Sonsini Goodrich & Rosati, join Rich Bendis on BioTalk to preview the event taking place live on September 21st, 2022 at USP in Rockville. For the first time in its history, this yearโ€™s Crab Trap winner will be eligible for a package of prizes worth more than $50,000.

Prizes for the qualifying Crab Trap winner include:

  • A $10,000 cash prize from Wilson Sonsini
  • A $5,000 cash from Montgomery County (for a firm headquartered in Montgomery County)
  • A one-year residency at JLABS @ Washington, D.C.
  • Preclinical CRO services from Noble Life Sciences.

Listen now via Apple https://apple.co/3Kr1FKU, Google https://bit.ly/3e46gGS, Spotify https://spoti.fi/3ctQ4Os, or Amazon Podcasts https://amzn.to/3qbvtSB

Read More
BioTalk Crab Trap Preview gif

7th Annual BioHealth Capital Region Crab Trap Preview

By News Archive

BioTalk Crab Trap Preview gif

Crab Trap Judges and Sponsors, Sally Allain, MSc., MBA Head, JLABS @ Washington, DC Johnson & Johnson Innovation โ€“ JLABS, Srujana Cherukuri, Ph.D., Chief Executive Officer, Noble Life Sciences, Inc. & Lora Green, Partner, Wilson Sonsini Goodrich & Rosati, join Rich Bendis on BioTalk to preview the event taking place live on September 21st, 2022 at USP in Rockville. For the first time in its history, this yearโ€™s Crab Trap winner will be eligible for a package of prizes worth more than $50,000.

Prizes for the qualifying Crab Trap winner include:

  • A $10,000 cash prize from Wilson Sonsini
  • A $5,000 cash from Montgomery County (for a firm headquartered in Montgomery County)
  • A one-year residency at JLABS @ Washington, D.C.
  • Preclinical CRO services from Noble Life Sciences.

Listen now via Apple https://apple.co/3Kr1FKU, Google https://bit.ly/3e46gGS, Spotify https://spoti.fi/3ctQ4Os, or Amazon Podcasts https://amzn.to/3qbvtSB

Read More
Cn hz grad 3c rgb lg 062017 png 4800ร—1200

Childrenโ€™s National Innovation Day aims to advance pioneering pediatric life science projects – Children’s National

By News Archive

Cn hz grad 3c rgb lg 062017 png 4800ร—1200Pioneering life science projects focused on improving pediatric care will be on display at the Childrenโ€™s National Research & Innovation Campus when the hospital hosts its 2022 Innovation Day on Friday, August 26. Hosted by Childrenโ€™s National Innovation Ventures, the programโ€™s goal is to showcase life sciences and healthcare projects that are mature enough to look for a co-developer, strategic partner, investor or licensing vehicle.

โ€œFor us, a successful Innovation Day means we are able to match these entrepreneurs with the strategic partner they need at this stage of their device development journey,โ€ says Kolaleh Eskandanian, Ph.D., M.B.A., P.M.P., vice president and chief innovation officer at Childrenโ€™s National Hospital and executive director of the Sheikh Zayed Institute for Pediatric Surgical Innovation.

ย 

Read More
Maryland Logo

Governor Hogan Announces Marylandโ€™s State Small Business Credit Initiative Programs Now Open

By News Archive

Maryland LogoANNAPOLIS, MDโ€”Governor Larry Hogan today announced Maryland programs funded by the State Small Business Credit Initiative (SSBCI) are open. Up to $198 million in federal small business relief is being administered by three state agencies: the Maryland Department of Housing and Community Development (DHCD), the Maryland Department of Commerce, and the Maryland Technology Development Corporation (TEDCO). These agencies will use funds to expand and enhance nine existing state business lending and investment programs.

 

Read More
1544228918022

Kwame Ulmer to appear….

By News Archive

1544228918022Who doesnโ€™t like a rooftop networking social? If youโ€™re a fellow University of Virginia Darden School of Business alum and plan to attend our Alumni Weekend, join us on Saturday. See details, below.

ย 

Read More

AstraZeneca Reportedly Seeking Bolt-On Opportunities, could Abandon Vaccines | BioSpace

By News Archive

Pascal Claude Roland Soriot
23 May 1959 (age 63)
France - WikipediaAstraZenecaย CEO Pascal Soriot raised questions Tuesday about the companyโ€™s future in vaccines while hinting at potential M&A activity on the near horizon.

In anย interviewย withย Reuters,ย Soriot discussed the company’s plans, which he said include building on its portfolio of antibody therapies. AstraZeneca is also considering bolt-on acquisitions in oncology and cardiovascular areas, Soriot said.

Getting out of the COVID-19 Vaccine Business?

Overall, in the COVID-19 space, the company has shifted its resources to antibody therapies.

Image: Pascal Claude Roland Soriot – 23 May 1959 (age 63) France – Wikipedia

Read More
Vaccitech logo

Finance Manager (US) – Vaccitech

By Uncategorized

Vaccitech logoThis is a rare opportunity to be the first Finance Team hire in our Maryland office to expand our UK-based finance team. As a US Finance Manager, you will be responsible for all-finance related activities in our US operations out of Maryland, ranging from financial accounting, management account to budgeting, financial planning and control. You will be responsible for building and growing the finance team and processes as we expand in the USA and work closely with the world-class science team based in Maryland. Having listed on NASDAQ in 2021, Vaccitech is growing rapidly both organically and though M&A and is excited to continue building its presence in the USA.

Click here to learn more.

522nd edition, August 23, 2022

By BHI Weekly Newsletter Archives





Trouble Viewing This Email: Click Here
 

August 23, 2022

FOUNDING MEMBER OF

5th Annual BioHealth Capital Region - Investment Conference

5th Annual BioHealth Capital Region - Investment Conference

 

Maryland’s RoosterBio and Seattle’s AGC Biologics Announce Collaboration to Accelerate Manufacturing of Cell and Exosome Therapies

SEATTLE, Aug. 16, 2022 (GLOBE NEWSWIRE) — AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced today a strategic partnership with RoosterBio Inc., a leading supplier of human mesenchymal stem/stromal cells (hMSCs), highly engineered media, and bioprocess development services.

The partnership creates an end-to-end solution for the development and production of hMSC and exosome therapeutics leveraging RoosterBio’s well-established cell and media products and process development services, coupled with AGC Biologics’ global cell and gene therapy manufacturing capabilities.

Read More

Biotech And Drug Development (Audio) – Bloomberg

Dr. Amrie Grammer, co-founder of AMPEL BioSolutions, joins the show to discuss biotech and her company Hosted by Paul Sweeney and Matt Miller.

Read More

Novavax Submits Application to the U.S. FDA for Emergency Use Authorization for Novavax COVID-19 Vaccine, Adjuvanted as a Booster in Adults Aged 18 and Older
  • If authorized, Novavax' vaccine would be the first protein-based COVID-19 booster for adults
  • If authorized, the Novavax COVID-19 Vaccine, Adjuvanted could be used as a booster dose for adults aged 18 and older vaccinated with any other currently available COVID-19 vaccine

GAITHERSBURG, Md., Aug. 15, 2022 /PRNewswire/ — Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that it submitted an application to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) of its protein-based COVID-19 Vaccine, Adjuvanted for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as a homologous and heterologous booster in adults aged 18 and older.

Read More

Biotechnology Investment Incentive Tax Credit (BIITC) Accepting 2023 Applications

The fiscal year 2022 program is now closed.  The fiscal year 2023 program will begin accepting applications as follows: Commerce will begin accepting Form B QMBC applications on 8/23/2022, and Form A Investor applications on 9/7/2022. Additional information is available under the “Apply” section.

BIITC provides an investor with a refundable State income tax credit for an eligible investment in a Qualified Maryland Biotechnology Company (QMBC). The program supports investment in seed and early stage biotech companies to promote and grow the biotech industry in Maryland.

Read More

 

D.C. Area Life Sciences Market Down to 1.4% Vacancy – Commercial Observer

The Washington, D.C./Baltimore region continued to see a tightening in its life sciences real estate market.

In particular, the region saw a decrease in life sciences vacancy in the second quarter of 2022, dropping from 3.6 percent to 1.4 percent since last year, according to CBRE’s latest national life sciences report.

Image: THE RECENT DEAL FOR THE TWINBROOK OFFICE CENTER HIGHLIGHTS THE DEMAND FOR LIFE SCIENCES SPACE IN THE MARYLAND SUBURBS OF D.C. PHOTO: BY NEWMARK

Read More

8 new high priority funding opportunities

We just released 8 new high priority funding opportunities where your company can make a difference in meeting the needs of cancer patients… Please see the solicitation and join our webinar on August 24th….

Read More

Technical.ly: 2 new medtech startups will spin out of Johns Hopkins research fund grants

Two new medical startups, focusing on addressing vision loss and catheter-associated urinary tract infections (UTIs), are on the horizon thanks to the $200,000 in grants the research teams received from the Johns Hopkins University’s Louis B. Thalheimer Fund for Translational Research.

14 researchers applied to the Thalheimer Fund, which was created to provide seed funding for proof-of-concept and validation studies of inventions coming out of Hopkins. The awards from the fund range from $25,000 to $100,000.

“We are excited to have received strong applications for disruptive technologies with commercialization potential that can have a future impact on human health and well-being,” Nicole Snell, associate director of ventures at Johns Hopkins Technology Ventures’ (JHTV) FastForward accelerator, which helps university-affiliated founders commercialize their technologies, said in a statement.

Read More

Don’t get distracted over ARPA-H fight; let’s win the bigger prize | Maryland Daily Record

Congress has approved a new agency — the Advanced Research Projects Agency for Health (ARPA-H) — that will ‘supercharge’ breakthrough medical research and provide over $1 billion in new research funding.

A fight has broken out, however, over ARPA-H’s headquarters’ location. The Maryland congressional delegation is working to locate it in state, but when a majority in Congress senses a chance to put a prestigious scientific headquarters in their home districts, Maryland likely will not win this battle.

Read More

Home | About BHI | BHI News | Programs | Partners | Contact

Copyright AA(C) BioHealth Innovation 2022
All Rights Reserved.


IBBR-Logo

Institute for Bioscience and Biotechnology Research Awarded $6.9M to Design and Test a Vaccine to Combat Hepatitis C

By News Archive

Mon, Aug 22, 2022

HCV envelope-antibody interaction

The National Institute of Allergy and Infectious Disease (NIAID) awarded a $6.9 million grant to researchers at the Institute for Bioscience and Biotechnology Research (IBBR) to design a vaccine to combat the virus that causes Hepatitis C, an illness that affects an estimated 71 million people worldwide.  Hepatitis C Virus (HCV) puts people at heightened risk for severe liver disease, including fibrosis, cirrhosis, and hepatocellular carcinoma (liver cancer).  Although treatments are available, an HCV vaccine currently does not exist to help prevent infections and reduce the global burden of the disease.

Read More

Search

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.